Improving insight into radiobiology and radionuclide therapy

Journal of Nuclear Medicine

Volumn 45, Issue 7, 2004, Pages 1104-1105

  Goldsmith, Stanley J ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; LUTETIUM 177; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LU 177; MONOCLONAL ANTIBODY Y 90; OCTREOTIDE; RHENIUM 166; SAMARIUM 153; SOMATOSTATIN DERIVATIVE; STRONTIUM 89; TIN 87M; UNCLASSIFIED DRUG; YTTRIUM 90; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT;

CARCINOID; DOSIMETRY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG HALF LIFE; EXTERNAL BEAM RADIOTHERAPY; FOOD AND DRUG ADMINISTRATION; GAMMA RADIATION; HISTOPATHOLOGY; HUMAN; ISOTOPE LABELING; METASTASIS; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; PANCREAS ISLET CELL CARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIOBIOLOGY; SHORT SURVEY; UNSPECIFIED SIDE EFFECT; BODY BURDEN; KIDNEY TUMOR; METABOLISM; METHODOLOGY; NOTE; RADIOMETRY; RADIOTHERAPY; TISSUE DISTRIBUTION;

BODY BURDEN; HUMANS; KIDNEY NEOPLASMS; RADIOBIOLOGY; RADIOISOTOPES; RADIOMETRY; RADIOPHARMACEUTICALS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; TISSUE DISTRIBUTION;

EID: 4043177731     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (9)

1. Quimby E. The development of radiation dosimetry in nuclear medicine. In: Medical Radionuclides: Radiation Dose and Effects. Washington, DC: U.S. Atomic Energy Commission; 1970:7-15. AEC Symposium Series 20.
2. 111In-DTPA] octreotide. J Nucl Med. 2004;45:1168-1171
3. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999;26:1439-1447.
4. 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur J Nucl Med. 2001;28:426-434.
5. 90Y-DOTATOC) in the treatment of neuroendocrine tumors: a clinical phase II study. Ann Oncol. 2001;12:941-945.
6. Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analog [(177)Lu-DOTA(0), Tyr(3) octreotate. Eur J Nucl Med Mol Imaging. 2003;30:417-422.
7. Bander NH, Trabulsi EJ, Kostakoglu L, et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol. 2003;170:1717-1721.
8. O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med. 1995;36:1902-1909.
9. Bardies M, Chatal JF. Absorbed fractions of 22 potential beta-emitting radionuclides for internal radiotherapy. Phys Med Biol. 1994;39:961-981.